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Self-assembly of a-synuclein resulting in protein aggregates of diverse
morphology has been implicated in the pathogenesis of Parkinson’s
disease and other neurodegenerative disorders known as synucleino-
pathies. Apart from its biomedical relevance, this aggregation process is
representative of the interconversion of an unfolded protein into nano-
structures with typical amyloid features. We have used in situ tapping
mode atomic force microscopy to continuously monitor the self-assembly
of wild-type a-synuclein, its disease-related mutants A30P and A53T,
and the C-terminally truncated variant a-synuclein(1–108). Different
aggregation modes were observed depending on experimental conditions,
i.e. pH, protein concentration, polyamine concentration, temperature and
the supporting substrate. At pH 7.5, in the absence of the biogenic poly-
amines spermidine or spermine, elongated sheets 1.1(^0.2) nm in height
and presumably representing individual b-sheet structures, were formed
on mica substrates within a few minutes. Their orientation was directed
by the crystalline substructure of the substrate. In contrast, sheet forma-
tion was not observed with hydrophobic highly oriented pyrolytic graph-
ite substrates, suggesting that negatively charged surfaces promote
a-synuclein self-assembly. In the presence of spermidine or spermine
5.9(^1.0) nm high spheroidal structures were preferentially formed,
sharing characteristics with similar structures previously reported for
several amyloidogenic proteins and linked to neurotoxicity. a-Synuclein
spheroid formation depended critically on polyamine binding to the C
terminus, revealing a promoting effect of the C terminus on a-synuclein
assembly in the bound state. In rare cases, fibril growth from spheroids
or preformed aggregates was observed. At pH 5.0, fibrils were formed
initially and incorporated into amorphous aggregates in the course of the
aggregation process, providing evidence for the potential of amyloid fibril
surfaces to act as nucleation sites in amorphous aggregation. This study
provides a direct insight into different modes of a-synuclein self-assembly
and identifies key factors modulating the aggregation process.
q 2004 Elsevier Ltd. All rights reserved.
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Introduction
The structural transition of the abundant protein
a-synuclein from its monomeric form to aggregates
rich in b-conformation has been implicated in the
pathogenesis of Parkinson’s disease (PD) and
other neurological disorders.1,2 Insoluble a-synu-
clein constitutes the main component of Lewy
bodies and Lewy neurites, dense intra-neuronal
inclusions of fibrillar and granular material that
0022-2836/$ - see front matter q 2004 Elsevier Ltd. All rights reserved.
E-mail addresses of the corresponding authors:
v.subramaniam@tnw.utwente.nl; tjovin@gwdg.de
Abbreviations used: Ab, Alzheimer’s b-amyloid
peptide; AFM, atomic force microscopy; EPR, electron
paramagnetic resonance; ESI-MS, electrospray ionization
mass spectrometry; HOPG, highly oriented pyrolytic
graphite; NMR, nuclear magnetic resonance; PD,
Parkinson’s disease; wt, wild-type; BCA, bicinchoninic
acid.
doi:10.1016/j.jmb.2004.04.051 J. Mol. Biol. (2004) 340, 127–139
define PD neuropathologically.1 Three missense
mutations in the a-synuclein gene (A30P, A53T
and E46K) have been linked to rare early-onset
familial forms of PD, providing further evidence
of the relevance of a-synuclein for PD.3,4,60
Neuronal cell death seems to be a consequence of
increased a-synuclein toxicity upon formation of
aggregated structures, although the mechanism
of toxicity remains unclear. Well-defined aggre-
gation intermediates might account for much of
the toxicity, a notion also suggested for other
amyloidogenic proteins.2,5 – 8
a-Synuclein belongs to the group of natively
unfolded proteins lacking ordered secondary struc-
ture in vitro in physiological buffers.9 However,
upon incubation at elevated temperatures with
agitation, aggregates that share features typical of
amyloid, e.g. fibrillar morphologies and high
b-structure content, are formed and are remi-
niscent of the in vivo inclusions.10 –13 Electron para-
magnetic resonance (EPR) and protease digestion
studies concordantly report that the central 70–80
amino acid residues of the 140 amino acid protein
constitute the aggregate core.14,15 Whereas this
region of the protein achieves a b-sheet confor-
mation in the aggregated state, the C-terminal
region comprising residues 103–140 remains
unstructured.14 This is probably a result of electro-
static repulsion within the C terminus as 14 out of
the 37 C-terminal amino acid residues are acidic.
Although the C terminus is not incorporated into
the aggregate core, it modulates the aggregation
process. C-terminal truncated fragments aggregate
faster than full-length a-synuclein, revealing
that the C terminus hinders aggregation.12,16,17 In
addition, the C terminus can interact with cationic
compounds such as metal ions by virtue of the
accumulation of acidic residues, resulting in
accelerated aggregation.6,18 – 21 The polyamines
putrescine, spermidine and spermine, naturally
occurring polycations, are particularly effective in
the promotion of a-synuclein assembly.22 Their
binding site has been localized to the C terminus
(residues 109–140) by NMR.23
Other factors leading to an accelerated in vitro
aggregation of a-synuclein are lower pH21,24 and
the disease-related A53T mutation.12,25 – 28 Studies
of the aggregation kinetics of the A30P mutant are
inconclusive, with reports of faster aggregation,26
similar aggregation speed,12 or slower fibrillation
but faster monomer consumption relative to the
wild-type protein.25,27,28
Multimeric a-synuclein adopts a number of
different morphologies, depending on aggregation
incubation time and solution conditions. The
earliest species detected by atomic force
microscopy (AFM) demonstrate a bead-like struc-
ture with heights of 2–6 nm.13,25,27,29 At later stages
of the aggregation process, these globular struc-
tures are replaced by fibrillar species with distinc-
tive morphologies. Apart from mature fibrils with
heights of ,10 nm, smaller fibrils with heights of
approximately 5 nm are formed, and have been
proposed to be protofilaments.13,25 In addition,
annular species with diameters of 7–10 nm are
found in early, pre-fibrillar fractions of a-synuclein
incubations.5,30 Under conditions linked to strong
shielding of the negative charges in the C terminus,
such as low pH or high metal ion or polyamine
concentrations, a-synuclein aggregates exhibit an
amorphous morphology, although the staining
characteristics of amyloid are retained.20 – 22
The morphologies of different amyloidogenic
peptides and proteins in the aggregated state
show striking similarities, suggesting a common
mode of assembly and potential toxicity.31 Recent
studies indicate that the early, pre-fibrillar aggrega-
tion intermediates possess the highest toxicity.7,8
The in vitro toxicity of such soluble oligomers
from different peptides and proteins is inhibited
by a structure-specific antibody, implying a
common, structure-based mechanism of toxicity.8
The complexity of the aggregation process aris-
ing from the structural polymorphism of the
diverse intermediates and the dependence on
solution conditions implies that direct and con-
tinuous observation of the reaction would be very
desirable. In situ tapping mode AFM under liquid
is a powerful tool for continuous observation of
amyloid assembly.32 – 34 The method enables the
repeated imaging of mechanically delicate samples
in physiological buffers and allows for selection
of precisely defined solution conditions. In this
study, we investigated the self-assembly of
a-synuclein by in situ AFM.
Results
The following conditions were adopted for the
Figure 1. Surface-templated sheet formation by a-synuclein. Time series of 0.8 mm £ 0.8 mm AFM height images. The
experiment was performed at 33 8C in 25 mM Tris–HCl (pH 7.5), supplemented with 1 mM putrescine utilizing a mica
substrate. At t ¼ 0 monomeric a-synuclein was added to a final concentration of 8 mM. The height bar represents 5 nm.
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AFM studies. (i) The liquid cell was filled with the
buffer (typically 25 mM Tris–HCl (pH 7.5)) and
additives of choice and an initial image of the
surface was acquired to confirm the absence of
contaminating particles. (ii) Monomeric (according
to analytical gel-filtration) a-synuclein was injected
into the fluid cell and the assembly process moni-
tored by continuous acquisition of AFM scans for
,45 minutes. (iii) The temperature was generally
adjusted to either 33 8C or 45 8C by use of a custom
tandem Peltier controller between the scanning
head and the liquid cell. (iv) Measurements were
generally performed at two different final protein
concentrations (8 mM and 40 mM) in the absence
and presence of one of the biogenic polyamines
putrescine, spermidine or spermine at a final
concentration of 1 mM.
In this study, we examined the full-length wild-
type a-synuclein, the disease-related mutants with
substitutions A53T and A30P, as well as a C-term-
inally truncated variant of the wild-type protein
comprising amino acid residues 1–108 (syn(1–
108)), thus lacking the polyamine-binding site.
Two substrates of different chemical nature,
freshly cleaved mica and highly oriented pyrolytic
graphite (HOPG), were utilized to investigate the
role of surface hydrophilicity/hydrophobicity in
the aggregation process. Using this methodology,
we were able to observe the formation of a-synu-
clein aggregates of different morphologies.
Assembly of 1.1 nm high, oriented sheets on
hydrophilic mica
Figure 1 shows a time-course of wild-type
a-synuclein self-assembly on a mica substrate in
25 mM Tris–HCl (pH 7.5) at a protein concen-
tration of 8 mM in the presence of 1 mM putrescine
at 33 8C. Under these conditions the surface
became covered within a few minutes with
elongated sheet-like structures with a height of
1.1(^0.2) nm ðn ¼ 70Þ. The sheet lengths increased
during the course of the experiment, indicating
that the assembly proceeded as a surface phenom-
enon, as was also manifested by a preferential
alignment along two specific directions. Two-
dimensional Fourier transforms of height images
from six different experiments (one of them
shown in Figure 2A) revealed an angle of
120(^2)8 between the two axes, presumably reflect-
ing the pseudo-hexagonal geometry of the mica
(001) surface.35 Sheet formation was not observed
when the hydrophilic mica substrate was replaced
with the hydrophobic HOPG, giving further
Figure 2. Condition-dependence of sheet formation.
A, A 0.5 mm £ 0.5 mm AFM height image; 33 8C; buffer,
25 mM Tris–HCl (pH 7.5), 1 mM putrescine; substrate,
mica; protein concentration, 8 mM a-synuclein wt; t,
13 minutes. The height bar represents 5 nm. Inset, 2D
Fourier transform of the image. B, A 0.64 mm £ 0.64 mm
AFM height image; 33 8C; buffer, 25 mM Tris–HCl (pH
7.5), no polyamine addition; substrate, mica; protein con-
centration, 40 mM a-synuclein wt; t, 24 minutes. The
height bar represents 5 nm. C, A 0.35 mm £ 0.35 mm
AFM height image; 45 8C; buffer, 25 mM Tris–HCl (pH
7.5), 1 mM putrescine; substrate, mica; protein concen-
tration, 40 mM a-synuclein wt; t, 25 minutes. The height
bar represents 5 nm. D, A 0.35 mm £ 0.35 mm AFM
height image; 45 8C; buffer, 25 mM Tris–HCl (pH 7.5),
1 mM putrescine; substrate, mica; protein concentration,
40 mM a-syn(1–108); t, 16 minutes. The height bar rep-
resents 2.5 nm. E, Distribution of the lateral spacing of
a-synuclein wild-type sheets, measured as the distance
between the sheet axes. Only distances of ,15 nm were
considered; n ¼ 139. F, A 0.5 mm £ 0.5 mm AFM height
image; 33 8C; buffer, 25 mM Tris–HCl (pH 7.5), 1 mM
putrescine; substrate, mica; protein concentration,
40 mM a-synuclein A30P; t, 30 minutes. The height bar
represents 3.5 nm. G, A 0.5 mm £ 0.5 mm AFM height
image; 33 8C; buffer, 25 mM Tris–HCl (pH 7.5), 1 mM
putrescine; substrate, mica; protein concentration,
40 mM a-synuclein A53T; t, four minutes. The height bar
represents 3.5 nm. Reported times indicate the time
elapsed since monomer injection.
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support for a specific surface-dependent growth
mechanism. Sheets were also formed in the
absence of putrescine at a protein concentration of
40 mM (Figure 2B). However, at a protein concen-
tration of 8 mM, sheets were formed in the presence
of 1 mM putrescine (Figure 1), but not in the
absence of the polyamine. Thus, both the protein
and the putrescine concentration affected sheet for-
mation. Experiments carried out at 45 8C did not
reveal any temperature dependence of the aggre-
gate morphology.
The individual sheets formed from wild-type
a-synuclein were well resolved even in experi-
ments in which the mica surface was saturated
(Figure 2C). Analysis of the lateral spacing of
sheets, measured as the distance between axes,
yielded the distance distribution shown in
Figure 2E (only distances ,15 nm were con-
sidered). Lateral spacings below 10 nm were
encountered only rarely and spacings of less than
8 nm were not observed. It is surprising that the
individual sheets were generally well resolved,
since object profiling by AFM is distorted due to
convolution with the tip geometry (nominal tip
radius 5–40 nm). In fact, deconvolution calcu-
lations led to an estimation of sheet width as
,5 nm, i.e. the sheet width was distinctly smaller
than the minimal lateral spacing between sheets.
Consequently, the minimal lateral spacing must
have originated from steric exclusion involving
the object detected by AFM as well as additional
unresolved structures.
The acidic C terminus of a-synuclein is not
incorporated into the core of mature fibrils.14,15,36 If
the same situation was applied to the elongated
sheets, the negatively charged C terminus might
act as a spacer dictating the minimal separation
due to charge repulsion. To test for such a possi-
bility, in situ AFM experiments were performed
with truncated a-synuclein syn(1–108) lacking the
C terminus. Although sheet-like structures were
formed by syn(1–108) (Figure 2D), they were less
well resolved compared to those of wild-type
a-synuclein. Parts of the mica surface appeared to
be covered with diffuse layers of protein material
instead of discrete sheets, implying a role of the C
terminus in the regulation of the lateral spacing of
full-length a-synuclein sheets.
Both disease-related mutants, A30P and A53T,
formed sheet-like structures with heights of
,1 nm. Whereas self-assembly from A30P was
indistinguishable from wild-type aggregates
(Figure 2F), A53T aggregation occurred faster
(full surface coverage was achieved in ,1 minute)
and resulted in less well organized sheets (Figure
2G). We conclude that the A53T mutant has a
greater tendency for self-assembly than the wild-
type and A30P mutant.
Rapid formation of 6 nm high spheroids under
conditions linked to accelerated fibrillation
In the presence of 1 mM spermidine or sper-
mine, formation of sheets was not observed.
Instead, a-synuclein assembled primarily into
5.9(^1.0) nm ðn ¼ 94Þ high spherical or ellipsoidal
particles with apparent widths of 15–20 nm
(Figure 3). The dimensions of the individual
spheroids did not change during the course of the
experiment after their first appearance on the sur-
face. Thus, their formation presumably occurs
in solution independent of the substrate surface.
In situ AFM experiments were carried out under
various conditions to identify factors promoting/
inhibiting spheroid formation.
Both the identity of the polyamine utilized
(spermidine and spermine were required for
spheroid assembly, putrescine was ineffective
under the conditions employed) and its concen-
tration affected the aggregation process. Figure 4
depicts aggregates formed at 45 8C from 8 mM pro-
tein solutions in the presence of 0.2 mM (A) and
1 mM (B) spermidine. In the presence of 0.2 mM
spermidine the 1.1 nm high surface-aligned sheets
were formed, whereas in 1 mM spermidine the
protein assembled preferentially into the 6 nm
high spheroids.
The protein concentration was an additional
factor influencing spheroid formation. Figure 4C
displays minor coverage of the mica surface with
unordered protein at an a-synuclein concentration
of 8 mM (t ¼ 33 8C, 1 mM spermine). In contrast,
at 40 mM protein and otherwise unchanged
conditions, the formation of spheroids was exten-
sive (Figure 4D).
Increased temperature was also associated with
Figure 3. Spheroid formation by a-synuclein. A, Time series of 0.8 mm £ 0.8 mm AFM height images. The experiment
was performed at 33 8C in 25 mM Tris–HCl (pH 7.5), supplemented with 1 mM spermine utilizing a mica substrate.
At t ¼ 0 monomeric a-synuclein was added to a final concentration of 40 mM. The height bar represents 15 nm. B, The
0.25 mm £ 0.25 mm AFM height image obtained from the same series 74 minutes after monomer injection.
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a stronger tendency for spheroid formation. These
structures were not observed in experiments
carried out at 33 8C with 8 mM protein and 1 mM
spermidine or spermine (Figure 4C), but formed
readily at 45 8C under otherwise identical con-
ditions (Figure 4B).
In summary, spheroid formation was promoted
by greater polyamine charge and concentration,
protein concentration and temperature, factors
known to accelerate a-synuclein fibrillation.22,24,37
We conclude that the spheroids may function as
important or essential on-pathway intermediates
in fibrillation.
In contrast to the growth of 1.1 nm fibrils,
spheroid formation was not impeded when the
hydrophilic mica substrate was replaced with
the hydrophobic HOPG (Figure 4E), supporting
the notion that this process occurred in solution,
i.e. not under the influence of the surface charac-
teristics. In the case of the C-terminally truncated
a-synuclein variant syn(1–108), spheroids did not
form. Instead, a layer of precipitated material
(height ,1 nm) without noticeable order appeared
with 40 mM syn(1–108) in the presence of 1 mM
spermine (Figure 4F). Thus, removal of the poly-
amine-binding site in the C terminus (residues
109–140) prevented spheroid formation.
Both disease-related mutants, A30P and A53T,
formed spheroids with heights of ,6 nm under
the conditions reported above for the wild-type
protein. Spheroid formation of the A30P mutant
was indistinguishable from wild-type aggregates
(Figure 4G). However, fewer spheroids were
observed with the A53T mutant compared to
wild-type and A30P under identical conditions.
Instead, the substrate was rapidly covered with a
layer (height ,1 nm) of protein material without
apparent organization (Figure 4H). This rapid sur-
face precipitation was reminiscent of the situation
in the absence of polyamines or in the presence
of putrescine (Figure 2G), providing further
evidence for a susceptibility of the A53T to precipi-
tation on negatively charged surfaces.
Protofibril growth from spheroids
Scanning larger areas of the mica surface under
conditions yielding spheroid aggregates revealed
the presence of fibrillar structures with a height
of ,6 nm as rare occurrences (Figure 5A and B).
Although we cannot provide direct evidence for
a relation of the ,6 nm high fibrils to mature
a-synuclein fibrils with typical heights of ,10 nm,
we denote the ,6 nm high structures as proto-
fibrils in the following discussion in distinction to
the ,10 nm mature fibrils. In general, the spher-
oids were stable as individual entities on the sur-
face. For example, the coalescence of two or more
individual spheroids was not observed. However,
in rare cases protofibril growth from spheroids
was observed (Figure 5C). Fibril elongation was
bidirectional in the case shown in Figure 5C, but
in other cases unidirectional. Heterogeneity in
Figure 4. Condition-dependence of spheroid for-
mation. The 1 mm £ 1 mm AFM height images (except
for G, 0.64 mm £ 0.64 mm). A, At 45 8C; buffer, 25 mM
Tris–HCl (pH 7.5), 0.2 mM spermidine; substrate,
mica; protein concentration, 8 mM a-synuclein wt; t,
18 minutes. B, At 45 8C; buffer, 25 mM Tris–HCl (pH
7.5), 1 mM spermidine; substrate, mica; protein concen-
tration, 8 mM a-synuclein wt; t, 17 minutes. C, At 33 8C;
buffer, 25 mM Tris–HCl (pH 7.5), 1 mM spermine; sub-
strate, mica; protein concentration, 8 mM a-synuclein
wt; t, 15 minutes. D, At 33 8C; buffer, 25 mM Tris–HCl
(pH 7.5), 1 mM spermine; substrate, mica; protein con-
centration, 40 mM a-synuclein wt; t, 19 minutes. E, At
33 8C; buffer, 25 mM Tris–HCl (pH 7.5), 1 mM spermine;
substrate, HOPG; protein concentration, 40 mM a-synu-
clein wt; t, 14 minutes. F, At 33 8C; buffer, 25 mM Tris–
HCl (pH 7.5), 1 mM spermine; substrate, mica; protein
concentration, 40 mM a-syn(1–108); t, 14 minutes. G, At
33 8C; buffer, 25 mM Tris–HCl (pH 7.5), 1 mM spermine;
substrate, mica; protein concentration, 40 mM a-synu-
clein A30P; t, 18 minutes. H, At 33 8C; buffer, 25 mM
Tris–HCl (pH 7.5), 1 mM spermine; substrate, mica;
protein concentration, 40 mM a-synuclein A53T; t,
28 minutes. The height bar represents 10 nm. Reported
times indicate the time elapsed since monomer injection.
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directionality and growth rates of amyloid fibrils
has been observed.38
We can propose two factors accounting for the
sparseness of the protofibril growth events. First,
interaction of the spheroids with the substrate
might perturb their potential for further assembly.
Second, the spheroids might constitute intrinsically
stable intermediates in the aggregation pathway. In
fact, spheroids are found in intermediate fractions
of a-synuclein incubated outside the AFM in
addition to mature a-synuclein fibrils (Figure 5D
and E). Spherical oligomers of somewhat smaller
height (2–6 nm) were observed before in a-synu-
clein incubations.25,27,29
Whereas protofibril growth could be imaged by
in situ AFM, growth of the mature fibrils was not
observed. In situ AFM experiments were repeated
in the presence of low concentrations of fibrillar
a-synuclein aggregates preformed outside of the
AFM. After acquiring images of these seeding
structures, monomeric a-synuclein was added and
fibril formation was monitored continuously.
Mature fibrils did not grow further during the
time of the experiment, although the growth of
fibrils distinctly smaller than mature fibrils was
observed. Figure 5F shows a time-course of
a-synuclein wild-type self-assembly on a mica sub-
strate in 20 mM sodium phosphate (pH 7.0) at
protein concentrations of 8 mM for the injected
monomeric protein and 0.06 mM for the pre-aggre-
gated fibrillar protein in the presence of 1.3 mM
putrescine at 50 8C. Recruitment of monomeric
a-synuclein into the preformed structures, result-
ing in their elongation, was the predominant
assembly mechanism, emphasizing the potential
of these structures to seed fibril growth. The pre-
formed structure consisted of a few adjoined fibril-
lar elements and exhibited a variable height in the
range of 5–12 nm, suggesting that it represented
a conglomerate of protofibrils possibly originating
Figure 5. Protofibril growth observed by in situ AFM.
A, The 0.25 mm £ 0.25 mm AFM height image; 45 8C;
buffer, 25 mM Tris–HCl (pH 7.5), 1 mM spermidine; sub-
strate, mica; protein concentration, 40 mM a-synuclein
wt; t, 47 minutes. The height bar represents 15 nm.
B, Cross-section of image A. C, Time series of
0.31 mm £ 0.17 mm AFM height (top half) and amplitude
(bottom half) images. At 45 8C; buffer, 25 mM Tris–HCl
(pH 7.5), 1 mM spermidine; substrate, mica; protein con-
centration, 40 mM a-synuclein wt. The height bar rep-
resents 15 nm. D, A 0.45 mm £ 0.45 mm ex situ AFM
height image; 100 mM a-synuclein wt was incubated at
37 8C in 25 mM Tris–HCl (pH 7.5), and an aliquot
removed when thioflavin T fluorescence reached ,5%
of its final value; substrate, mica; final protein concen-
tration in AFM, 0.1 mM. The height bar represents
15 nm. E, Cross-section of image D. F, Time series of
1.4 mm £ 1.4 mm AFM height images. At 50 8C; buffer,
20 mM sodiumphosphate (pH 7.0), 1.3 mM putrescine,
supplemented with 0.063 mM pre-aggregated a-synu-
clein wt; substrate, mica; monomeric protein concen-
tration, 8 mM a-synuclein wt. The height bar represents
20 nm. G, Time-dependence of the fibril length of the
four individual fibrils marked by color in the 32.0 min
image in F. Note that double tip artifacts caused by
protein adsorption to the tip are present in images A
and C. Reported times indicate the time elapsed since
monomer injection.
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from a dissected mature fibril. The heights of
the growing fibrils were typical for protofibrils
(,5 nm), demonstrating once again that, in con-
trast to mature fibril growth, protofibril growth
was observable by in situ AFM. Interestingly,
according to the time dependence of fibril length,
elongation did not proceed continuously but rather
via a stop-and-run mechanism, as is evident from
the plateaus observed temporarily for each of
the protofibrils in Figure 5G. The average fibril
growth rate was in the order of 10 nm/minute.
However, due to the stepwise progression of fibril-
lation the maximum growth rate for a fibril
observed between two images was ,50 nm/min-
ute, a value significantly greater than the average
rate. This value represented a lower limit for the
maximum growth rate, inasmuch as the time
required for the corresponding growth step might
have been below the temporal resolution of the
in situ AFM instrument (2.1 minutes per image).
Fibrils are formed initially at low pH and lead
to amorphous aggregates
Incubating a-synuclein in vitro at low pH leads
to accelerated aggregation with the formation of
amorphous rather than fibrillar aggregates.21,24 The
latter retain certain features of amyloid structures,
e.g. the ability to bind the fluorescent dye thio-
flavin T. We performed in situ AFM experiments
at pH 5.0 and 45 8C (in the absence of polyamines)
in order to follow continuously the formation of
these aggregates. During the course of aggregation,
fibrils constituted a distinct intermediate stage
(Figure 6A). After rapid formation in the first few
minutes, further fibril growth virtually ceased.
Instead, deposition of amorphous material on the
fibril surface became the primary mode of a-synu-
clein assembly, eventually leading to large amor-
phous aggregates with a height (up to 150 nm;
Figure 6B) exceeding greatly that of the indi-
vidual fibrils (,6–8 nm). We propose that the
acidic C terminus is partially neutralized upon
pH reduction, such that electrostatic repulsion
between fibrils is reduced and both monomeric
and multimeric a-synuclein are able to make favor-
able interactions with the fibril surface. The pre-
sence of both fibrillar and amorphous aggregates
at pH 5.0 is consistent with experiments performed
outside of the AFM.21
Discussion
The data presented here demonstrate the appli-
cability of in situ tapping mode AFM for obser-
vation of a-synuclein self-assembly. The method
offers important advantages. First, it allows con-
tinuous monitoring of individual aggregate
species. Second, as is recapitulated in Figure 7, it
is capable of providing high-resolution images of
pre-fibrillar spheroid aggregates as well as the
elongated sheet structures with heights consistent
with that of a single b-sheet. Third, imaging in
fluid offers the opportunity to apply various solu-
tion conditions, a crucial advantage considering
the strong solution dependence of a-synuclein
aggregation. The AFM setup employed in this
work additionally permits the adjustment of the
sample temperature, an essential feature given the
influence of temperature on amyloid formation.
A prerequisite for imaging of an object by AFM is
its adhesion to the substrate surface. The selected
substrate might bias the assembly process,32 but
this effect can be assessed by utilizing substrates
of different chemical nature. In fact, several obser-
vations point towards a role of surface character-
istics in a-synuclein aggregation and amyloid
formation in general, both in vitro and in vivo.39
a-Synuclein associates with membrane surfaces,40,41
which leads to modulated aggregation proper-
ties.42 – 45 The same holds true for anionic micelle
surfaces.46 The presence of a surface in in situ
AFM therefore offers the opportunity to investigate
the surface dependence of a-synuclein assembly
even to the point of mimicking conditions similar
to those in vivo.
Surface-templated formation of sheets with
heights consistent with single b-sheets
Formation of 1.1(^0.2) nm high sheets was the
Figure 6. Fibrillar and amorphous aggregation at pH 5.0. A, Time series of 2.5 mm £ 2.5 mm AFM amplitude images.
The experiment was performed at 45 8C in 50 mM Na–Mes (pH 5.0), supplemented with 0.1 mM MgCl2 utilizing a
mica substrate. At t ¼ 0 monomeric wild-type a-synuclein was added to a final concentration of 5 mM. B, Cross-
sections of the AFM height images corresponding to the 17 minute (green) and 52 minute (red) amplitude images
from A.
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major self-assembly mode on mica substrates in
the absence of the polyamines spermidine and
spermine. The mica surface served as a template
in this assembly process, as indicated by the fol-
lowing three observations. First, sheets grew in
length on the surface, but elongated sheets did
not appear spontaneously from solution. Second,
sheet formation was dependent on the nature of
the substrate and did not occur on hydrophobic
HOPG in contrast to hydrophilic mica. Third, the
sheets aligned along two specific directions that
were separated by an angle of 120(^2)8, reflecting
the pseudo-hexagonal surface geometry of mica
(001). Interestingly, only two of the three directions
expected for a perfect pseudo-hexagonal surface
geometry governed the sheet directions. A similar
phenomenon was reported for epitaxial growth of
para-sexiphenyl thin films on mica and explained
on the basis of the crystal structure of mica.47
After cleavage in the (001) plane, the uppermost
oxygen layer exhibits a pseudo-hexagonal geome-
try, while hydroxide and fluoride anions reside
in the octahedral layer below. These anions are
slightly dislocated from the center of the hexagonal
openings of the top layer, resulting in a twofold
symmetry of mica (001) surfaces.35,47 The obser-
vation of two instead of three preferred directions
for sheet formation thus indicates that this assem-
bly process is influenced by the precise location of
negative charges in the octahedral layer below the
top oxygen layer.
The height of the sheet-like aggregates of
1.1(^0.2) nm was in the range expected for a single
b-sheet. X-ray diffraction studies of a-synuclein
fibrils yield a spacing of 1.0–1.1 nm between the
b-sheets comprising the fibril.12 The coinciding
dimensions of the b-sheets constituting the fibrils
and the sheets observed by in situ AFM suggest
that the structures assembled on mica might con-
stitute individual, elongated b-sheets, possibly
sharing details of structural organization with
those incorporated in the fibrils. The growth of
b-sheet assemblies is likely to proceed by continu-
ous binding of monomers to the b-strand located
at the sheet end via hydrogen bonds. In this
manner, the hydrogen bond network is extended
and highly organized, and stable structures as
typified by amyloid fibrils are formed.31,48 Such an
assembly mode requires that the hydrogen-
bonding interface of the b-strand located at the
sheet end points into the direction of sheet growth.
Consequently, the individual b-strands constitut-
ing the sheet structures have to be oriented perpen-
dicular to the long sheet axis, forming a cross-
b-structure in analogy to the organization of
b-sheets encountered in amyloid fibrils. Similar
conclusions were drawn from in situ AFM studies
of a different amyloidogenic peptide, Alzheimer’s
b-amyloid peptide (Ab).33 Ab forms elongated
sheet structures with heights of 1.0–1.2 nm, also
exhibiting a distinct directionality of sheet align-
ment that reflects the lattice structure of the sub-
strate. Likewise, elastin peptides that are known
to assemble into aggregates rich in b-structure
were reported to form substrate–lattice-oriented,
sheet-like structures with a height of ,1.2 nm and
a deconvolved width of ,3 nm in in situ AFM
experiments.49
Importantly, the substrate required for sheet for-
mation from a-synuclein was different from the
one required for Ab and elastin peptide sheet
assembly. Ab and elastin peptides form sheets on
HOPG, but not on mica. The opposite is true for
a-synuclein, showing that substrate-directed for-
mation of b-sheets does not occur exclusively on
hydrophobic surfaces. Amyloidogenic peptides
and proteins thus appear to have a tendency to
assemble on surfaces into single b-sheets, testifying
to their potential to adopt b-structures, yet with
different individual preferences for surfaces of
different chemical nature. The surface properties
required for b-sheet formation by a specific protein
will consequently depend on its primary structure.
Preferential assembly of a-synuclein on a nega-
tively charged substrate such as mica is in accord-
ance with previous observations of accelerated
fibrillation in the presence of anionic micelle
surfaces46 and polyanions such as glycosamino-
glycans50 and DNA (D.C., W.H., V.S. & T.M.J.,
unpublished results). Interestingly, a-synuclein
Figure 7. Surface view of the main aggregate morphologies observed in this study. A, Sheets; B, spheroids; C, proto-
fibril and spheroids. A, The area displayed corresponds to a section of Figure 4A. B, Experimental conditions as for
Figure 4B. C, The area displayed corresponds approximately to Figure 5A.
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itself is an acidic protein with a noticeable excess of
negative charges at neutral pH. However, the
acidic residues are concentrated in the C terminus
(mainly residues 104–140) with the remainder
of the protein exhibiting a positive net charge at
neutral pH. In this context the comparison of
sheet formation of full-length with C-terminally
truncated a-synuclein is informative, suggesting
that the C terminus is not incorporated into the
sheet assemblies, analogous to the situation in
mature fibrils,14,15,36 but remains in solution. In this
scenario, the positively charged N-terminal and
central regions of the protein monomer can asso-
ciate with the negatively charged substrate,
whereas the C-terminal region does not interact
with the surface. Possible mediators of favorable
protein–surface interactions are the five KXK
motifs present in the N-terminal part of the
a-synuclein sequence. In a b-sheet conformation,
two positively charged lysine residues would be
located adjacently, facing in the same direction.
Interestingly, model peptides with alternating
hydrophobic and hydrophilic amino acids contain-
ing KXK motives were shown to assemble on mica,
yielding nanofibers of similar morphology as
reported here for a-synuclein.51 Moreover, por-
phyrin self-assembles on mica in the presence of
polylysine into rod-like structures that exhibit
the same directionality observed for a-synuclein
sheets,52 providing further evidence for a potential
role of lysine residues in substrate-governed pep-
tide and protein self-assembly.
While sheet formation from wild-type a-synu-
clein and the A30P mutant were indistinguishable,
A53T assembly occurred faster and the final struc-
tures appeared to be less organized. Similarly, in
the presence of spermidine and spermine, A53T
formed fewer spheroids compared to wild-type
and A30P a-synuclein, but precipitated rapidly on
the mica surface. These observations are com-
patible with previous studies reporting altered
aggregation behavior, i.e. faster aggregation, as a
consequence of the A53T mutation, which could
account for its pathogenic effect.12,25 – 28 The present
study adds a further perspective to this issue in
that it indicates that surface-directed aggregation
might be of importance for the increased toxicity
of the A53T mutant.
Spheroids are formed rapidly when
polyamines are bound to the C terminus and
constitute intermediates on the pathway
towards fibrillar aggregates
In the presence of the polyamines spermidine
and spermine, a-synuclein readily assembled into
spheroids with heights of approximately 6 nm.
Spheroid formation seemed to be a surface-
independent process. First, the dimensions of the
individual spheroids did not change in time after
their first appearance. Second, the chemical nature
of the substrate did not alter spheroid formation.
Third, they were also encountered in incubations
performed outside of the AFM. We conclude that
increasing numbers of spheroids on the substrate
with time reflects their surface-independent forma-
tion in solution. However, it cannot be absolutely
excluded that surfaces might generally, i.e. inde-
pendent of their chemical nature, assist spheroid
formation.
The ability to assemble into spheroid structures
appears to be a common property of amyloido-
genic proteins and peptides. Several such struc-
tures with dimensions similar to those given here
for a-synuclein have been reported in the litera-
ture and are referred to in different ways, e.g. as
micelles, diffusible non-fibrillar ligands, single
unit aggregates or soluble oligomers. For a-synu-
clein itself, spherical assemblies of 2–6 nm height
were observed.13,25,27,29 Ab forms oligomeric units
with heights between 4 nm and 6 nm.33,34,53 – 56 The
prion protein Sup35 and the immunoglobin light
chain SMA assemble into spherical oligomers
exhibiting heights of 2–4 nm and ,5.5 nm,
respectively.39,57 Recently, evidence has accumu-
lated that such pre-fibrillar assemblies and not
amyloid fibrils account for most of the toxicity of
amyloidogenic proteins and peptides.7,8,53 Kayed
et al.8 prepared Ab-covered gold particles (mean
diameter ,5.3 nm) as molecular mimics for soluble
oligomers and used them as antigens in antibody
production.8 The antibody obtained inhibits the
in vitro toxicity of different amyloidogenic peptides
and proteins, including a-synuclein. The mecha-
nism by which soluble oligomers mediate their
toxicity is unclear. Membrane permeabilization
represents one potential candidate and was pro-
posed as the toxic function of pre-fibrillar
a-synuclein.5,58 Considering the suggested key role
of spheroid structures for amyloid toxicity, the
identification of factors promoting their formation
by techniques such as in situ AFM is highly infor-
mative. In the experiments described here, the
polyamines spermidine and spermine promoted
spheroid formation. The naturally occurring poly-
amines putrescine, spermidine and spermine have
been shown to accelerate amyloid aggregation of
a-synuclein and their binding site was identified
as the C terminus (residues 109–140).22,23 The bind-
ing constants were between 0.6 mM and 10 mM
with stronger binding linked to the higher number
of positive charges and length of the polyamine.
Electrostatic interactions of the negatively charged
aspartate and glutamate residues in the C terminus
of a-synuclein with the positively charged amino
groups of the polyamine represent the driving
force of binding, resulting in neutralization of
charges specifically in the region between residues
109 and 140. Spheroid formation required the
presence of one of the stronger binding polyamines
spermidine or spermine, which saturate the pro-
tein to ,60% and ,25%, respectively, under the
conditions used here based on the binding con-
stants obtained from NMR.23 In contrast, 1 mM
putrescine with only ,9% saturation was ineffec-
tive in spheroid formation. Importantly, spheroids
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were not formed from the C-terminally truncated
protein syn(1–108) lacking the polyamine-binding
site. We conclude that with its C terminus electro-
statically shielded by bound polyamines full-
length a-synuclein cannot be regarded as func-
tionally equivalent to a truncated molecule lacking
the C terminus. Thus, polyamine binding to the C
terminus promotes spheroid formation not only
indirectly by releasing the inherent inhibition by
the negatively charged C terminus, but also
directly by a yet unknown mechanism. The
bridging of protein monomers by the multivalent
polyamines would be one plausible mechanism.
Alternatively, spheroid formation might be
enhanced as a consequence of structural effects of
polyamine binding on protein regions remote
from the binding site but crucial for self-assembly.
Such secondary effects of polyamine binding were
suggested by NMR intensity changes in the N
terminus and central region upon polyamine
binding.23 Up to now, the sole effect of the C termi-
nus on a-synuclein self-assembly has been ascribed
to a deceleration of aggregation.12,16,17 With regard
to spheroid formation, the results presented here
indicate that this inhibitory function can reverse
into an aggregation-promoting function upon
polyamine binding.
Apart from the identity of the polyamine
employed in the in situ AFM experiments, further
factors, namely polyamine concentration, protein
concentration and temperature, affected spheroid
formation. All of these factors are known to bias
fibrillation and spheroid formation of a-synu-
clein,22,24,37 suggesting that spheroids possibly
constitute on-pathway intermediates in the process
of fibrillation. This view is supported by the obser-
vation that the 6 nm spheroids can evolve into
fibrillar structures of similar height. The spheroid-
protofibril transition was also described for Ab,
Sup35 and the immunoglobin light chain
SMA.33,34,39,54,55,57 The observation of spheroids as
intermediates in a-synuclein incubations outside
of the AFM and the sparseness of protofibril
growth from spheroids encountered in in situ
AFM together suggest that the spheroid–proto-
fibril transition might constitute a key step in the
fibrillation process.
Another explanation for the stability of spher-
oids in in situ AFM could be that their interaction
with the substrate inhibits further growth. The
surface-governed formation of protein sheets
clearly demonstrates that the substrate influences
a-synuclein assembly. Moreover, the fibrils visual-
ized by in situ AFM were distinctly thinner than
the mature fibrils representing the major mor-
phology observed in samples that were aggregated
outside of the AFM. The same phenomenon was
observed for amylin, Ab and immunoglobin light
chain SMA fibrillation on mica substrates,32,34,39
demonstrating that the presence of the mica sur-
face modulates the accessible fibril morphologies.
Finally, interactions with the substrate might also
account for the rather surprising observation of a
stop-and-run mechanism for protofibril elongation.
Direct observation of amyloid fibrillation from
b2-microgobulin by total internal reflection fluor-
escence microscopy did not support such a mecha-
nism, although the growth rates of individual
fibrils varied.59 In in situ AFM, heterogeneous inter-
actions of the protofibril ends with the surface
could result in variable activation barriers for
further recruitment of pre-fibrillar a-synuclein
from solution, giving rise to the observed stop-and
run-phases.
Incorporation of a-synuclein fibrils into
amorphous aggregates is governed by the
charge state of the fibril surface
At pH 5.0, a-synuclein first assembled into fibril-
lar structures that were subsequently covered with
protein precipitates of amorphous morphology. It
should be noted that the amorphous aggregates
formed at low pH differ from unspecific protein
aggregates in that they apparently share structural
properties with amyloid aggregates.21 The detec-
tion of amorphous aggregates originating from
a-synuclein fibril surfaces could be explained by a
potential of these surfaces to act as nucleation
sites in amorphous aggregation under certain
charge conditions. Alternatively, the amorphous
aggregates might form in solution and the initially
formed fibril surfaces could constitute the sub-
strate for their deposition that is preferred to the
charged mica plane. In both cases, the modulated
electrostatic properties of the fibril surfaces upon
pH reduction are the likely cause for their
increased tendency to interact rather unspecifically
compared to neutral pH. At neutral pH, the
a-synuclein C terminus is not incorporated into
the fibril core but located on the fibril surface.14,15,36
If the same was true at pH 5.0, the fibril surface
would carry a distinctly decreased charge at pH
5.0 compared to neutral pH due to the neutrali-
zation of the numerous acidic C-terminal residues.
Consequently, hydrophobic interactions with the
fibril surface would be facilitated, potentially
culminating in rather unspecific amorphous aggre-
gation. Unspecific interactions of protein aggre-
gates with cellular compounds other than the
amyloidogenic protein itself are thought to be a
critical step in the pathogenesis of protein mis-
folding diseases.7
The observation and analysis of the diverse
assembly modes presented here highlight many
features that are important for aggregation of
a-synuclein. In relation to the neurotoxicity of
amyloid proteins, the detection of spontaneous
formation of 6 nm high spheroid structures depen-
dent on the solution conditions is very informative.
These structures resemble the formerly described
soluble oligomers, which were suggested to be the
major toxic species in amyloid diseases.8 Our
experiments show that the formation of these
structures is strongly favored when polyamines
are bound to the C terminus (residues 109–140).
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Apart from spheroids, assembly of a-synuclein can
yield 1.1 nm high protein sheets, possibly individ-
ual b-sheets with a cross-b conformation similar
to that present in amyloid fibrils. Interestingly,
these sheets are formed preferentially on mica in a
surface-templated manner, pointing towards the
capability of a-synuclein to self-assemble on nega-
tively charged surfaces. In the cellular context
such surfaces are represented by anionic mem-
brane phospholipid surfaces, with which a-synu-
clein readily associates in vitro, resulting in
modulated aggregation properties.40 – 45 The exper-
imental setup employed in this work can be used
for further investigation of the sheet growth and
spheroid formation processes with respect to the
underlying mechanisms and the identification of
potential assembly inhibitors.
Materials and Methods
Preparation of wild-type, mutant and truncated
a-synuclein
Recombinant human wild-type, A53T and A30P
a-synuclein were expressed and purified as described21
using plasmid pT7-7 encoding for the proteins (courtesy
of the Lansbury laboratory, Harvard Medical School,
Cambridge, MA). The carboxy-terminally truncated
a-synuclein fragment syn(1–108) was amplified by PCR
from full-length wild-type a-synuclein and subcloned
into pT7-7. The sequence was validated by DNA sequen-
cing. Expression and purification of the truncated
proteins was performed essentially as described for full-
length a-synuclein.21 The identity of all proteins was
verified by electrospray ionization mass spectrometry
(ESI-MS). Protein concentrations were obtained using
the bicinchoninic acid (BCA) assay and validated by
absorbance measurements at 275 nm using an extinction
coefficient of 1400 M21 cm21 per tyrosine residue.
Atomic force microscopy
AFM images were acquired on a Digital Instruments
Multimode Nanoscope IIIa scanning probe microscope
using an E-Scanner (Digital Instruments, Santa Barbara,
CA). The scanner was equipped with a custom-built
temperature controller comprising two tandem Peltier
elements controlling the temperature of the sample and
the scanner, respectively. This setup allowed for setting
accurately defined elevated sample temperatures, while
maintaining the scanner under constant thermal con-
ditions. Freshly cleaved mica or HOPG were used as
substrates for each experiment. The respective buffer
supplemented with the desired concentration of poly-
amine and aliquots from solutions of preformed aggre-
gates, when required, was deposited on the substrate in
a total volume of either 80 ml or 90 ml. Polyamine stock
solutions were prepared by diluting the respective
chloride salts in water. The pH effect of polyamine
addition to the in situ AFM solutions was ,0.05 pH
unit. For pH 5.0 experiments, MgCl2 was added at a
final concentration of 0.1 mM. The sample temperature
controller was set to the desired temperature (33 8C,
45 8C or 50 8C) and kept constant during the experiment.
The fluid cell was not sealed with an O-ring. The volume
of liquid was kept constant by replacing evaporated
water via a syringe, thus ensuring that the position of
the meniscus did not change. After acquiring an initial
image of the clean mica or HOPG surface (or a surface
region comprising preformed aggregates, respectively),
either 10 ml or 20 ml of monomeric a-synuclein in the
same buffer as that added previously to the fluid cell
were added via a syringe to yield a final volume of
100 ml and final concentrations as indicated in the text
and Figure legends.
AFM images were acquired continuously at a scan
rate between 1.00 Hz and 2.96 Hz with 256 lines per
image, i.e. data acquisition took between 1.44 minutes
and 4.27 minutes per image. Imaging was performed in
tapping mode with either NP-S (Digital Instruments;
nominal spring constant 0.32 N/m) or OMCL-
TR800PSA (Olympus; nominal spring constant 0.57 N/
m) cantilevers at an oscillation frequency of ,9 kHz.
In general, the indicated times refer to the moment
when data acquisition for the respective image was
completed. In contrast, time data in Figure 5G corre-
spond to the time imaging of the particular fibril was
accomplished.
Formation of preformed aggregates
Fibrillar a-synuclein aggregates were obtained by
incubating 100 mM (Figure 5D and E) or 250 mM
(preformed structures in Figure 5F and G) solutions of
a-synuclein at 37 8C in glass vials under constant stirring
with micro stir bars. The fibrillation process was fol-
lowed by thioflavin T binding as described elsewhere21
and stopped after a constant thioflavin T fluorescence
intensity indicated that a steady-state was reached.
Acknowledgments
We thank Helmut Richmann for the construction
of the tandem Peltier temperature controller. We
are indebted to Herming Urlaub for the ESI-MS
measurements. W.H. acknowledges support from
the Stiftung Stipendien-Fonds des Verbandes der
Chemischen Industrie and the Bundesministerium
fu¨r Bildung und Forschung.
References
1. Goedert, M. (2001). Alpha-synuclein and neuro-
degenerative diseases. Nature Rev. Neurosci. 2,
492–501.
2. Goldberg, M. S. & Lansbury, P. T., Jr (2000). Is there a
cause-and-effect relationship between a-synuclein
fibrillization and Parkinson’s disease? Nature Cell.
Biol. 2, E115–E119.
3. Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide,
S. E., Dehejia, A., Dutra, A. et al. (1997). Mutation in
the a-synuclein gene identified in families with
Parkinson’s disease. Science, 276, 2045–2047.
4. Kruger, R., Kuhn, W., Muller, T., Woitalla, D.,
Graeber, M., Kosel, S. et al. (1998). Ala30Pro mutation
in the gene encoding a-synuclein in Parkinson’s dis-
ease. Nature Genet. 18, 106–108.
5. Lashuel, H. A., Hartley, D., Petre, B. M., Walz, T. &
Lansbury, P. T., Jr (2002). Amyloid pores from
pathogenic mutations. Nature, 418, 291.
a-Synuclein Self-assembly Observed by In Situ AFM 137
6. Kim, Y. S., Lee, D., Lee, E. K., Sung, J. Y., Chung,
K. C., Kim, J. & Paik, S. R. (2001). Multiple ligand
interaction of a-synuclein produced various forms
of protein aggregates in the presence of Ab25-35,
copper, and eosin. Brain Res. 908, 93–98.
7. Bucciantini, M., Giannoni, E., Chiti, F., Baroni, F., For-
migli, L., Zurdo, J. et al. (2002). Inherent toxicity of
aggregates implies a common mechanism for protein
misfolding diseases. Nature, 416, 507–511.
8. Kayed, R., Head, E., Thompson, J. L., McIntire, T. M.,
Milton, S. C., Cotman, C. W. & Glabe, C. G. (2003).
Common structure of soluble amyloid oligomers
implies common mechanism of pathogenesis.
Science, 300, 486–489.
9. Weinreb, P. H., Zhen, W., Poon, A. W., Conway, K. A.
& Lansbury, P. T., Jr (1996). NACP, a protein impli-
cated in Alzheimer’s disease and learning, is
natively unfolded. Biochemistry, 35, 13709–13715.
10. Hashimoto, M., Hsu, L. J., Sisk, A., Xia, Y., Takeda,
A., Sundsmo, M. & Masliah, E. (1998). Human
recombinant NACP/a-synuclein is aggregated and
fibrillated in vitro: relevance for Lewy body disease.
Brain Res. 799, 301–306.
11. Giasson, B. I., Uryu, K., Trojanowski, J. Q. & Lee,
V. M. (1999). Mutant and wild type human a-synu-
cleins assemble into elongated filaments with distinct
morphologies in vitro. J. Biol. Chem. 274, 7619–7622.
12. Serpell, L. C., Berriman, J., Jakes, R., Goedert, M. &
Crowther, R. A. (2000). Fiber diffraction of synthetic
a-synuclein filaments shows amyloid-like cross-b
conformation. Proc. Natl Acad. Sci. USA, 97,
4897–4902.
13. Conway, K. A., Harper, J. D. & Lansbury, P. T., Jr
(2000). Fibrils formed in vitro from a-synuclein and
two mutant forms linked to Parkinson’s disease are
typical amyloid. Biochemistry, 39, 2552–2563.
14. Der-Sarkissian, A., Jao, C. C., Chen, J. & Langen, R.
(2003). Structural organization of a-synuclein fibrils
studied by site-directed spin labeling. J. Biol. Chem.
278, 37530–37535.
15. Miake, H., Mizusawa, H., Iwatsubo, T. & Hasegawa,
M. (2002). Biochemical characterization of the core
structure of a-synuclein filaments. J. Biol. Chem. 277,
19213–19219.
16. Crowther, R. A., Jakes, R., Spillantini, M. G. &
Goedert, M. (1998). Synthetic filaments assembled
from C-terminally truncated a-synuclein. FEBS
Letters, 436, 309–312.
17. Murray, I. V., Giasson, B. I., Quinn, S. M., Koppaka,
V., Axelsen, P. H., Ischiropoulos, H. et al. (2003).
Role of a-synuclein carboxy-terminus on fibril
formation in vitro. Biochemistry, 42, 8530–8540.
18. Paik, S. R., Shin, H. J., Lee, J. H., Chang, C. S. & Kim,
J. (1999). Copper(II)-induced self-oligomerization of
a-synuclein. Biochem. J. 340, 821–828.
19. Nielsen, M. S., Vorum, H., Lindersson, E. & Jensen,
P. H. (2001). Ca2þ binding to a-synuclein regulates
ligand binding and oligomerization. J. Biol. Chem.
276, 22680–22684.
20. Uversky, V. N., Li, J. & Fink, A. L. (2001). Metal-
triggered structural transformations, aggregation,
and fibrillation of human a-synuclein. A possible
molecular link between Parkinson’s disease and
heavy metal exposure. J. Biol. Chem. 276,
44284–44296.
21. Hoyer, W., Antony, T., Cherny, D., Heim, G., Jovin,
T. M. & Subramaniam, V. (2002). Dependence of
a-synuclein aggregate morphology on solution
conditions. J. Mol. Biol. 322, 383–393.
22. Antony, T., Hoyer, W., Cherny, D., Heim, G., Jovin,
T. M. & Subramaniam, V. (2003). Cellular polyamines
promote the aggregation of a-synuclein. J. Biol. Chem.
278, 3235–3240.
23. Fernandez, C. O., Hoyer, W., Zweckstetter, M., Jares-
Erijman, E. A., Subramaniam, V., Griesinger, C. &
Jovin, T. M. (2004). NMR of a-synuclein complexes
with polyamines elucidates the mechanism and
kinetics of induced aggregation. EMBO J. 23,
2039–2046.
24. Uversky, V. N., Li, J. & Fink, A. L. (2001). Evidence
for a partially folded intermediate in a-synuclein
fibril formation. J. Biol. Chem. 276, 10737–10744.
25. Conway, K. A., Harper, J. D. & Lansbury, P. T., Jr
(1998). Jr accelerated in vitro fibril formation by a
mutant a-synuclein linked to early-onset Parkinson’s
disease. Nature Med. 4, 1318–1320.
26. Narhi, L., Wood, S. J., Steavenson, S., Jiang, Y., Wu,
G. M., Anafi, D. et al. (1999). Both familial Parkin-
son’s disease mutations accelerate a-synuclein aggre-
gation. J. Biol. Chem. 274, 9843–9846.
27. Conway, K. A., Lee, S. J., Rochet, J. C., Ding, T. T.,
Williamson, R. E. & Lansbury, P. T., Jr (2000). Accel-
eration of oligomerization, not fibrillization, is a
shared property of both a-synuclein mutations
linked to early-onset Parkinson’s disease: impli-
cations for pathogenesis and therapy. Proc. Natl
Acad. Sci. USA, 97, 571–576.
28. Li, J., Uversky, V. N. & Fink, A. L. (2001). Effect of
familial Parkinson’s disease point mutations A30P
and A53T on the structural properties, aggregation,
and fibrillation of human a-synuclein. Biochemistry,
40, 11604–11613.
29. Ding, T. T., Lee, S. J., Rochet, J. C. & Lansbury, P. T., Jr
(2002). Annular a-synuclein protofibrils are pro-
duced when spherical protofibrils are incubated in
solution or bound to brain-derived membranes. Bio-
chemistry, 41, 10209–10217.
30. Lashuel, H. A., Petre, B. M., Wall, J., Simon, M.,
Nowak, R. J., Walz, T. & Lansbury, P. T., Jr (2002).
a-Synuclein, especially the Parkinson’s disease-
associated mutants, forms pore-like annular and
tubular protofibrils. J. Mol. Biol. 322, 1089–1102.
31. Dobson, C. M. (2003). Protein folding and mis-
folding. Nature, 426, 884–890.
32. Goldsbury, C., Kistler, J., Aebi, U., Arvinte, T. &
Cooper, G. J. (1999). Watching amyloid fibrils grow
by time-lapse atomic force microscopy. J. Mol. Biol.
285, 33–39.
33. Kowalewski, T. & Holtzman, D. M. (1999). In situ
atomic force microscopy study of Alzheimer’s
b-amyloid peptide on different substrates: new
insights into mechanism of b-sheet formation. Proc.
Natl Acad. Sci. USA, 96, 3688–3693.
34. Blackley, H. K., Sanders, G. H., Davies, M. C.,
Roberts, C. J., Tendler, S. J. & Wilkinson, M. J. (2000).
In-situ atomic force microscopy study of b-amyloid
fibrillization. J. Mol. Biol. 298, 833–840.
35. Bailey, S. W. (1980). Structures of layer silicates. In
Crystal Structure of Clay Minerals and their X-ray
Identification (Brindley, G. W. & Brown, G., eds), pp.
2–196, Mineralogical Society, London.
36. Crowther, R. A., Daniel, S. E. & Goedert, M. (2000).
Characterisation of isolated a-synuclein filaments
from substantia nigra of Parkinson’s disease brain.
Neurosci. Letters, 292, 128–130.
37. Wood, S. J., Wypych, J., Steavenson, S., Louis, J. C.,
Citron, M. & Biere, A. L. (1999). a-Synuclein fibrillo-
genesis is nucleation-dependent. Implications for
138 a-Synuclein Self-assembly Observed by In Situ AFM
the pathogenesis of Parkinson’s disease. J. Biol. Chem.
274, 19509–19512.
38. DePace, A. H. & Weissman, J. S. (2002). Origins and
kinetic consequences of diversity in Sup35 yeast
prion fibers. Nature Struct. Biol. 9, 389–396.
39. Zhu, M., Souillac, P. O., Ionescu-Zanetti, C., Carter,
S. A. & Fink, A. L. (2002). Surface-catalyzed amyloid
fibril formation. J. Biol. Chem. 277, 50914–50922.
40. Davidson, W. S., Jonas, A., Clayton, D. F. & George,
J. M. (1998). Stabilization of a-synuclein secondary
structure upon binding to synthetic membranes.
J. Biol. Chem. 273, 9443–9449.
41. McLean, P. J., Kawamata, H., Ribich, S. & Hyman,
B. T. (2000). Membrane association and protein con-
formation of a-synuclein in intact neurons. Effect of
Parkinson’s disease-linked mutations. J. Biol. Chem.
275, 8812–8816.
42. Jo, E., McLaurin, J., Yip, C. M., St George-Hyslop, P.
& Fraser, P. E. (2000). a-Synuclein membrane inter-
actions and lipid specificity. J. Biol. Chem. 275,
34328–34334.
43. Lee, H. J., Choi, C. & Lee, S. J. (2002). Membrane-
bound a-synuclein has a high aggregation pro-
pensity and the ability to seed the aggregation of
the cytosolic form. J. Biol. Chem. 277, 671–678.
44. Narayanan, V. & Scarlata, S. (2001). Membrane bind-
ing and self-association of a-synucleins. Biochemistry,
40, 9927–9934.
45. Zhu, M. & Fink, A. L. (2003). Lipid binding inhibits
a-synuclein fibril formation. J. Biol. Chem. 278,
16873–16877.
46. Necula, M., Chirita, C. N. & Kuret, J. (2003). Rapid
anionic micelle-mediated a-synuclein fibrillization
in vitro. J. Biol. Chem. 278, 46674–46680.
47. Plank, H., Resel, R., Andreev, A., Sariciftci, N. S. &
Sitter, H. (2002). Structural relationship between
epitaxially grown para-sexiphenyl and mica (0 0 1)
substrates. J. Cryst. Growth, 237–239, 2076–2081.
48. Jaroniec, C. P., MacPhee, C. E., Bajaj, V. S., McMahon,
M. T., Dobson, C. M. & Griffin, R. G. (2004). High-
resolution molecular structure of a peptide in an
amyloid fibril determined by magic angle spinning
NMR spectroscopy. Proc. Natl Acad. Sci. USA, 101,
711–716.
49. Yang, G., Woodhouse, K. A. & Yip, C. M. (2002). Sub-
strate-facilitated assembly of elastin-like peptides:
studies by variable-temperature in situ atomic force
microscopy. J. Am. Chem. Soc. 124, 10648–10649.
50. Cohlberg, J. A., Li, J., Uversky, V. N. & Fink, A. L.
(2002). Heparin and other glycosaminoglycans
stimulate the formation of amyloid fibrils from
a-synuclein in vitro. Biochemistry, 41, 1502–1511.
51. Hong, Y., Legge, R. L., Zhang, S. & Chen, P. (2003).
Effect of amino acid sequence and pH on nanofiber
formation of self-assembling peptides EAK16-II and
EAK16-IV. Biomacromolecules, 4, 1433–1442.
52. Koti, A. S. R. & Periasamy, N. (2003). Self-assembly
of template-directed J-aggregates of porphyrin.
Chem. Mater. 15, 369–371.
53. Lambert, M. P., Barlow, A. K., Chromy, B. A.,
Edwards, C., Freed, R., Liosatos, M. et al. (1998).
Diffusible, nonfibrillar ligands derived from Ab1-42
are potent central nervous system neurotoxins. Proc.
Natl Acad. Sci. USA, 95, 6448–6453.
54. Nybo, M., Svehag, S. E. & Holm Nielsen, E. (1999).
An ultrastructural study of amyloid intermediates
in Ab1-42 fibrillogenesis. Scand. J. Immunol. 49,
219–223.
55. Harper, J. D., Wong, S. S., Lieber, C. M. & Lansbury,
P. T., Jr (1999). Assembly of Ab amyloid protofibrils:
an in vitro model for a possible early event in
Alzheimer’s disease. Biochemistry, 38, 8972–8980.
56. Yong, W., Lomakin, A., Kirkitadze, M. D., Teplow,
D. B., Chen, S. H. & Benedek, G. B. (2002). Structure
determination of micelle-like intermediates in amyl-
oid b-protein fibril assembly by using small angle
neutron scattering. Proc. Natl Acad. Sci. USA, 99,
150–154.
57. Serio, T. R., Cashikar, A. G., Kowal, A. S., Sawicki,
G. J., Moslehi, J. J., Serpell, L. et al. (2000). Nucleated
conformational conversion and the replication of
conformational information by a prion determinant.
Science, 289, 1317–1321.
58. Volles, M. J., Lee, S. J., Rochet, J. C., Shtilerman, M. D.,
Ding, T. T., Kessler, J. C. & Lansbury, P. T., Jr (2001).
Vesicle permeabilization by protofibrillar a-synu-
clein: implications for the pathogenesis and treat-
ment of Parkinson’s disease. Biochemistry, 40,
7812–7819.
59. Ban, T., Hamada, D., Hasegawa, K., Naiki, H. &
Goto, Y. (2003). Direct observation of amyloid fibril
growth monitored by Thioflavin T fluorescence.
J. Biol. Chem. 278, 16462–16465.
60. Zarrane, J. J., Alegre, J., Gomez-Esteban, J. C., Lez-
cano, E., Ros, R., Ampyero, I. et al. (2004). The new
mutation E46K of a-synuclein causes Parkinson and
Lewy body dementia. Ann. Neurol. 55, 164–173.
Edited by M. Yaniv
(Received 9 February 2004; accepted 9 April 2004)
a-Synuclein Self-assembly Observed by In Situ AFM 139
